🌅 Pre-Market Pulse

S&P Futures 7,523.50 ▲ +24.25 (+0.32%)	Nasdaq Futures 28,752.00 ▲ +138.50 (+0.48%)	Dow Futures 52,707.00 ▲ +280.00 (+0.53%)
10Y Treasury 4.68% ▼ -0.02%	US Dollar 101.29 ▲ +0.08 (+0.08%)	Bitcoin $65,221 ▼ -$116 (-0.18%)

Good morning! Monday, July 27, 2026 is off to a solid start, with futures pointing higher across the board and a handful of headline-grabbing stories in pharma, energy, and fashion ready to set the tone. AstraZeneca is pulling in two directions at once, argenx just dropped a $2.2 billion acquisition, and Shein finally cracked open its financials for the world to see. There is a lot to unpack before the opening bell, so let's get into it.

👀 What to Watch Today

The trading calendar is front-loaded with corporate catalysts this Monday. AstraZeneca (AZN) tops the watchlist after reporting a pair of contrasting headlines overnight, one showing solid 5% revenue growth powered by oncology, the other revealing that its rare disease drug Ultomiris missed the primary endpoint in a late-stage trial. Traders will be parsing how much the pipeline miss weighs against the otherwise healthy top-line growth.

Argenx (ARGX) will draw serious attention after announcing it will acquire Forte Biosciences (FBRX) for approximately $2.2 billion, adding the experimental autoimmune drug FB102 to its portfolio. Expect elevated volume and volatility in both ARGX and FBRX as the market digests the deal terms and what it means for argenx's pipeline strategy.

On the macro side, keep an eye on the dollar index sitting at 101.29 and Treasury yields nudging slightly lower across the curve. The 10-year at 4.68% and the 30-year at 5.16% are worth monitoring throughout the session as any shift in rate expectations can quickly reprice growth and tech names heading into the afternoon.

You must do this before the OpenAI IPO [ad]

🌏 Overnight Recap

Asian markets traded mixed overnight with no dominant regional theme, while European equities opened cautiously higher as investors processed a fresh round of corporate earnings and geopolitical developments. TotalEnergies (TTE) made news out of France after announcing it will appeal a Paris court ruling that ordered the oil major to align its business strategy with climate change adaptation goals. The legal fight adds regulatory uncertainty to TTE's outlook and could attract fresh scrutiny from ESG-focused investors.

Shein captured attention globally after releasing financial disclosures as part of its Hong Kong IPO filing. The fast-fashion giant posted a $99 million quarterly loss, weighed down by slowing sales after the U.S. eliminated the de minimis import duty exemption for small packages, plus a significant one-time accounting charge. The filing gives markets their first real look at Shein's books and confirms that the regulatory environment for low-cost cross-border e-commerce has fundamentally shifted.

Bitcoin is trading slightly lower at $65,221, down a modest 0.18% overnight, suggesting crypto markets are in a holding pattern rather than reacting to any specific catalyst this morning. The mild softness in crypto is not creating any notable spillover into crypto-adjacent equities at this stage.

I’m shouting ‘Buy Now’ before this stock soars [ad]

📊 Pre-Market Movers

AstraZeneca (AZN) is the single most complex pre-market story of the morning. On one hand, revenue rose 5% in constant currency terms, driven by robust oncology performance, a segment that continues to carry the company's growth story. On the other hand, Ultomiris failing its late-stage trial in patients with a blood vessel complication after stem cell transplant is a meaningful pipeline setback in the rare disease space. Expect the stock to open with a wide bid-ask spread as buyers and sellers negotiate which headline wins.

Forte Biosciences (FBRX) is likely to pop sharply at the open following the argenx buyout announcement at approximately $2.2 billion. Acquisition targets almost always trade toward the deal price on day one, and FBRX should be no exception. Meanwhile, ARGX itself may face modest selling pressure as the market evaluates whether the price tag for FB102 is justified given the drug is still experimental.

Futures overall are painting a constructive picture, with S&P 500 futures up 0.32% to 7,523.50, Nasdaq futures gaining 0.48% to 28,752.00, and Dow futures adding 0.53% to 52,707.00. The broad-based strength suggests the session is setting up for a positive open barring any surprise macro data.

The grid just blinked red [ad]

🔍 Today's Watchlist

1. AZN: dual catalyst day with oncology revenue growth vs. Ultomiris trial miss creating a tug-of-war on sentiment
2. ARGX and FBRX: $2.2 billion acquisition announcement drives deal-day volatility and volume in both names
3. TTE: climate ruling appeal adds regulatory headline risk for the energy sector broadly
4. 10-Year Treasury at 4.68%: watch for any intraday yield movement that could reprice rate-sensitive growth stocks
5. Shein IPO filing: no direct US ticker but watch for read-through impact on SHPW, PDD, and fast-fashion peers like FAST and related retail names

🎯 The Morning Playbook

The playbook for today centers on selectivity rather than broad market conviction. Futures are green and the rate picture is modestly supportive with yields edging lower, but the biggest moves today will be stock-specific. Focus energy on AZN, ARGX, and FBRX rather than trying to call the broader tape.

For longer-term investors, the Shein IPO filing is worth reading carefully. The disclosure that slowing sales followed the end of the de minimis exemption is a real-world data point about how trade policy changes ripple through consumer spending and e-commerce models. That theme has legs well beyond a single IPO.

Mondays in a bull market tend to carry early optimism that needs a reason to sustain itself through the afternoon. Keep position sizing disciplined, let the opening volatility settle in the first 30 minutes, and let the actual price action confirm the pre-market narrative before committing. The edge today belongs to those who watch first and act second.

Do NOT Buy SpaceX – Do This Instead [ad]